RCS - Ondine Biomedical - Finalist for 2nd National Award for SSI reduction

Ondine BiomedicalAnnouncement

23/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251223:nRSW3736Ma&default-theme=true

RNS Number : 3736M  Ondine Biomedical Inc.  23 December 2025

23 December 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Finalist for 2nd National Award for SSI reduction

 Ondine and Mid Yorkshire Teaching NHS Trust shortlisted for Excellence in
Healthcare Partnership Award for Reducing Surgical Site Infections with Nasal
Photodisinfection

Second national award shortlist recognises successful partnership addressing
the NHS priority of reducing surgical site infections and antimicrobial
resistance.

Ondine Biomedical Inc (AIM: OBI) and Mid Yorkshire Teaching NHS Trust (Mid
Yorks) are finalists for the 'Partnership Working to Address National
Healthcare Priorities (Local Projects)' category at the prestigious 2026
Excellence in Healthcare Partnership (EHP) Awards.

This shortlisting recognises the successful collaboration between Ondine and
Mid Yorks to address one of the NHS's most pressing challenges: reducing
surgical site infections (SSIs) while limiting reliance on antibiotics. It
follows the Trust's introduction of Ondine's Steriwave(®) nasal
photodisinfection technology into orthopaedic surgery pathways at its
Pontefract and Pinderfields hospitals.

This is the partnership's second recent selection for a national awards
shortlist, underscoring nasal photodisinfection as an important
infection-prevention and cost-saving approach for the NHS which can help
address wait lists, currently exceeding six million patients. This recognition
comes on the heels of being named a finalist for the HSJ Partnership Award in
the category of 'Most Impactful Use of Technology on Clinical Practice'.

Implemented for patients undergoing hip and knee replacement surgery at Mid
Yorks' Pontefract and Pinderfields hospitals, the Steriwave intervention was
associated with a 71% reduction in post-surgical infections in hip surgery
over six months, with no SSIs observed in knee surgery during the evaluation
period. In addition to improving patient outcomes, the initiative delivered
meaningful cost savings by reducing avoidable complications and associated
hospital resource use.

The EHP Awards specifically celebrate collaborations that align with national
healthcare priorities, including patient safety, antimicrobial stewardship and
system efficiency. The Ondine-Mid Yorks partnership demonstrates how
clinically integrated innovation can deliver measurable benefits at a local
level while supporting broader NHS goals.

Since the initial pilot, Steriwave is now being used or evaluated by several
major hospitals across England in a range of surgical specialties, as well as
in intensive care, where immunocompromised patients are particularly
vulnerable to infection. Adoption has been driven in part by growing concern
over mupirocin resistance and poor patient compliance, which limit the
effectiveness of antibiotic-based nasal decolonisation.

Unlike antibiotics, photodisinfection rapidly destroys bacteria, viruses and
fungi without generating resistance, offering an effective, non-antibiotic
approach to infection prevention.

Carolyn Cross, CEO of Ondine, commented:

"This second recent shortlisting for a national award serves as a powerful
endorsement, highlighting the recognition of tangible solutions for reducing
surgical site infections. It clearly demonstrates what is possible when NHS
clinicians and industry partners collaborate to bring innovative approaches to
the real-world challenges facing our overstretched healthcare system.
Preventing surgical site infections is absolutely vital-not only for patient
safety, but also for driving hospital efficiency and supporting antimicrobial
stewardship."

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation
at Mid Yorkshire Teaching NHS Trust, added:

"Being shortlisted again reflects both the strength of this collaboration and
the value of introducing new approaches that genuinely improve patient care.
Patient safety is at the heart of everything we do, and we are proud to be
recognised again at a national level for the introduction of
photodisinfection."

For healthcare providers in the UK interested in Steriwave(®), the technology
is available through Ondine's distribution partner, Mölnlycke Health Care, a
global leader in medical solutions. For more information contact: Healthcare
Professionals Contact (https://www.molnlycke.com/en-gb/contact/) or
info.uk@molnlycke.com, or call +44 0800 917 4918.

About Steriwave(®) Nasal Photodisinfection

Steriwave nasal photodisinfection is a non-invasive and painless treatment
that uses a proprietary light-activated photosensitive agent to destroy
harmful bacteria, viruses, and fungi-including antibiotic-resistant strains-in
the nasal passages. The procedure takes five minutes and, unlike antibiotics,
is effective immediately and allows the normal nasal microbiome to recover
quickly, without fostering antimicrobial resistance, offering a powerful tool
in the fight against healthcare-associated infections.

About Excellence in Healthcare Partnership Awards

The Excellence in Healthcare Partnership Awards are organised by PMGroup
Worldwide Ltd and Visions4Health and are among the most respected honours
recognising collaborations between the NHS and its commercial partners that
deliver measurable improvements in patient care, efficiency and value.
Recognition at the EHP Awards highlights the strength and effectiveness of a
partnership and raises its profile across the NHS and beyond, reinforcing the
credibility and impact of the work being celebrated. Winners will be announced
at the awards ceremony on 5 February 2026.

 

Enquiries:

 Ondine Biomedical Inc.                                            www.ondinebio.com
 Carolyn Cross, CEO                                                +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                                     +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                                     +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                                  +44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico and several other
countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.

 

About Mölnlycke Health Care 

 

Mölnlycke Health Care is a world-leading MedTech company that specialises in
innovative solutions for wound care and surgical procedures. Mölnlycke
products and solutions are used daily by hospitals, health care providers and
patients in over 100 countries around the world. Founded in 1849, Mölnlycke
is owned by Investor AB and headquartered in Sweden. www.molnlycke.com
(http://www.molnlycke.com)

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGCBDDBUDDGUB



            Copyright 2019 Regulatory News Service, all rights reserved